Search results
Showing 8206 to 8220 of 8221 results
NICE recommends two CAR-T therapies, both given as one-off infusions, to treat aggressive forms of blood cancer.
We've updated our health inequalities web resource so that it maps NICE guidance to frameworks for children and young people.
An early introduction to NICE’s ongoing activity in virtual wards
How 'surrogate outcomes' influence long-term health outcomes
NICE working with international organisations to develop guidance.
People with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy.
New clot-busting drug recommended by NICE set to save NHS £millions
Giving a new clot-busting drug to people who have had a stroke could help save the NHS millions of pounds.
Statins a choice for more people to reduce risk of heart attacks and strokes
New evidence on the safety of statins means more people could benefit from them, new NICE draft guidance says.
NICE publishes final draft guidance on Enhertu after commercial discussions conclude
NICE does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.
NICE launches second consultation on genetic testing to guide treatment after a stroke
People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.
NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.
How NICE is ensuring its topic prioritisation decisions are grounded in lived experience
Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.
NICE collaboration on streamlined licensing and patient access process for new medicines
Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland.
Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer
Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer
How NICE manages the potential conflicts of interests of patient experts
People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.
This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.